Halozyme Therapeutics reports upbeat study results

Halozyme Therapeutics Inc. (Nasdaq: HALO) positive topline results from a Phase 2 study of PEGPH20 in combination with ABRAXANE and gemcitabine to treat stage IV pancreas cancer patients. Shares of the biotechnology firm climbed $1.92 to close at $12.61.


Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.